Evidence-Based Guide

Asthma

Causes, classification, step therapy, GINA 2025 guideline updates, biologics, and when to seek emergency care.

How is asthma treated according to the latest guidelines?

Nearly 28 million people in the U.S. have asthma, and nearly all asthma deaths are avoidable with the right treatment and care, per the Asthma and Allergy Foundation of America. The GINA 2025 summary guide says adults and adolescents with asthma should not be treated with a short-acting beta-agonist (SABA, such as albuterol) alone, and that treatment should include an inhaled corticosteroid (ICS). Low-dose ICS-formoterol is the preferred reliever for adolescents and adults; used as needed, it reduces emergency visits or hospitalizations by 65% compared with SABA alone. Maintenance-and-reliever therapy (SMART) uses one ICS-formoterol inhaler both daily and as needed; in trials reviewed for the NAEPP 2020 Focused Updates, it reduced exacerbations by 32% compared with the same-dose ICS-LABA plus a SABA reliever in people 12 and older. Severe attack signs include talking in single words, sitting hunched forward, and peak flow at or below 50% of best; drowsiness, confusion or a silent chest are life-threatening. A licensed clinician, through telehealth or in-person evaluation, can confirm the diagnosis and recommend next steps.
Medically reviewed by Parth Bhavsar, MD. Updated August 11, 2026.

Key Takeaways

  • Nearly 28 million people in the U.S. have asthma, and nearly all asthma deaths are avoidable with the right treatment and care.[3]
  • GINA 2025 says adults and adolescents with asthma should not be treated with a short-acting beta-agonist (SABA) alone; low-dose ICS-formoterol is now the preferred reliever for adolescents and adults.[1]
  • SMART (Single Maintenance and Reliever Therapy) uses one ICS-formoterol inhaler for daily and as-needed use. In trials reviewed for the U.S. NAEPP 2020 update, it reduced exacerbations by 32% compared with the same-dose ICS-LABA plus a separate SABA reliever in people 12 and older.[2]
  • Six biologic therapies are used for severe asthma. One of them, tezepelumab (anti-TSLP), is approved regardless of blood eosinophil, IgE and FeNO levels, although it appears particularly effective in type 2 asthma.[4]
  • Up to 90% of people with asthma, depending on the device and population, do not use their inhalers correctly. Technique is not the only driver of poor control, but improving it has been linked to better asthma outcomes.[6]
Editorial medical illustration representing Asthma
Asthma: an evidence-based overview from the TeleDirectMD medical team.

Here is a fact that should trouble all of us in medicine: asthma still kills thousands of Americans every year (3,279 people in 2024), and nearly all of these deaths are avoidable with the right treatment and care.[3] That is not a vague aspiration; it is a clinical reality. Following an asthma action plan, taking asthma medicines as prescribed, reducing exposure to triggers, and getting medical help all reduce the risk of death.[3]

Nearly 28 million people in the United States have asthma.[3] Patients present with asthma every week, and the patterns are consistent: undertreated inflammation, overreliance on rescue inhalers, poor inhaler technique, and confusion about when symptoms cross the line from manageable to dangerous. These are all solvable problems.

The last several years have brought major changes in how we treat asthma. The GINA 2025 guidelines have restructured the approach to mild asthma, SMART therapy has simplified inhaler regimens, and biologic therapies have given us new tools for severe disease. This guide combines the current evidence with what I see in clinical practice. The aim here is to provide thorough, current, and honest information about what the evidence supports and what it does not.

What Causes Asthma?

Asthma is a chronic airway disease, usually characterized by chronic airway inflammation.[1] That idea of chronic inflammation is worth pausing on, because it explains why asthma behaves the way it does and why the treatment approach centers on inflammation control rather than just opening up the airways.

Three processes define asthma at a physiological level:

  • Airway inflammation: The bronchial lining is chronically inflamed, swollen, and producing excess mucus, even when you feel fine. This inflammation is why inhaled corticosteroids, which treat inflammation, are the bedrock of therapy.
  • Airway hyperresponsiveness: Asthmatic airways are hypersensitive and overreact to stimuli that would not bother a healthy person, such as cold air, exercise, allergens, and irritants. The smooth muscles surrounding the airways contract excessively, causing the characteristic wheezing and chest tightness.
  • Airway remodeling: Over time, chronic untreated inflammation can lead to structural changes in the airway wall, which is one reason early anti-inflammatory treatment matters. Early treatment with low-dose ICS is associated with better lung function than starting after symptoms have been present for more than 2–4 years.[1]

Triggers vs. Causes

This is a distinction I make with every asthma patient. Triggers are the things that provoke an asthma episode. GINA lists exposure to allergens you are sensitized to, smoking, vaping, and air pollution as risk factors for exacerbations, and notes that exacerbations are often triggered by viral upper respiratory infections.[1] Cold air, exercise, strong odors, and stress are other common triggers. Causes and risk factors relate to why someone has asthma in the first place: GINA lists allergy features and a family history of asthma or allergy among risk factors for childhood asthma persisting, and notes that asthma is more difficult to control in people with obesity.[1]

The practical implication is that avoiding triggers is important, but it is not sufficient. You can eliminate every known trigger from your environment and still have poorly controlled asthma if the underlying inflammation is not treated. Conversely, a patient on appropriate anti-inflammatory therapy can often tolerate trigger exposure that would have sent them to the emergency room before treatment.

Asthma Classification: Intermittent Through Severe Persistent

In the U.S. NAEPP system (Expert Panel Report 3), asthma severity is classified into four categories, intermittent, mild persistent, moderate persistent, and severe persistent, based on current impairment and risk. Initial treatment is guided by the severity category.[8] The values below are for people 12 and older.[8]

Classification Daytime Symptoms Nighttime Awakenings Lung Function (FEV1) Interference With Activity
Intermittent ≤2 days/week ≤2 times/month Normal between exacerbations; >80% predicted None
Mild Persistent >2 days/week, not daily 3–4 times/month ≥80% predicted Minor limitation
Moderate Persistent Daily >1 time/week, not nightly >60% but <80% predicted Some limitation
Severe Persistent Throughout the day Often 7 times/week <60% predicted Extremely limited

An important clinical point: severity is assessed at the initial evaluation, before treatment starts. Once a patient is on therapy, we switch to assessing asthma control at each visit, meaning how well the current regimen is keeping symptoms at bay.[8] A patient with moderate persistent asthma who is well controlled on their current medications does not need to be stepped up; equally, a patient with "mild" asthma who is having weekly symptoms on no treatment should not be left without a controller. In the NAEPP approach, patients are re-evaluated two to six weeks after a medication is started, and a step down can be considered once asthma has been stable for at least three months.[8] GINA similarly advises a review 1–3 months after starting treatment and considering a step down once asthma has been well controlled for 3 months or more.[1]

The GINA 2025 Paradigm Shift: What Has Changed and Why It Matters

The Global Initiative for Asthma (GINA) 2025 strategy reflects a major change in asthma management philosophy. The central message is straightforward but has enormous practical consequences: adults and adolescents with asthma should not be treated with a short-acting beta-agonist (SABA) alone.[1]

GINA 2025: The End of SABA-Only Treatment

For years, patients with mild intermittent asthma were prescribed an albuterol rescue inhaler and told to use it as needed. We now know this approach carries real risk: GINA notes that SABA-only treatment is associated with increased risk of exacerbations, worse lung function, and increased risk of death due to asthma.[1] GINA 2025 recommends that all adults, adolescents, and children aged 6–11 years receive treatment that includes ICS. In the preferred approach (Track 1), as-needed low-dose ICS-formoterol reduces emergency visits or hospitalizations by 65% compared with SABA alone.[1]

Track 1 vs. Track 2

GINA 2025 outlines two treatment tracks for adults and adolescents:[1]

  • Track 1 (Preferred): Uses low-dose ICS-formoterol as the reliever at every step. For Steps 1–2 (mild asthma), the recommended treatment is low-dose ICS-formoterol taken whenever needed to relieve symptoms, with no daily inhaler required. Step 3 is maintenance-and-reliever therapy (MART, also called SMART) with low-dose maintenance ICS-formoterol, and Step 4 is MART with medium-dose maintenance ICS-formoterol.
  • Track 2 (Alternative): Uses a SABA or ICS-SABA as the reliever. GINA describes it as an alternative approach when ICS-formoterol is not available, and it may also be considered for a patient with stable asthma and no exacerbations on their current treatment. At Step 1 there is no maintenance ICS; if the reliever is SABA, ICS is taken whenever SABA is used. Step 2 is low-dose maintenance ICS, Step 3 is low-dose maintenance ICS-LABA, and Step 4 is medium-dose maintenance ICS-LABA.

SMART Therapy: One Inhaler, Simpler Regimens, Better Outcomes

Single Maintenance and Reliever Therapy (SMART) is one of the most significant advances in practical asthma management. The concept is simple: a single ICS-formoterol combination inhaler is used both as the daily controller and as the reliever when symptoms happen.[2]

Why does this work? Formoterol is a long-acting beta-agonist with a rapid onset, which is why it can serve as a reliever.[2] Every time a patient reaches for their reliever, they receive both a bronchodilator for symptom relief and a dose of inhaled corticosteroid that treats the underlying inflammation driving the flare. The AAAAI notes that AIR and SMART help prevent serious asthma attacks better than using separate inhalers.[5] In trials reviewed for the NAEPP 2020 update, SMART reduced exacerbations by 32% compared with the same-dose ICS-LABA as daily controller plus a SABA reliever, in people 12 and older.[2]

In the U.S., the NAEPP 2020 Focused Updates (EPR-4) make SMART the preferred Step 3 and Step 4 therapy for people aged 4 and older with moderate to severe persistent asthma. The maximum total daily dose of formoterol should not exceed 8 puffs (36 µg) for ages 4 to 11 and 12 puffs (54 µg) for ages 12 and older.[2] GINA goes further, using ICS-formoterol as the reliever from Step 1.[1]

Decision Framework: Manage at Home, See a Doctor, or Go to the ER

All patients should have a written asthma action plan.[1] Plans are commonly organized around a traffic-light system of green, yellow, and red zones, as in the NHLBI template summarized below.[9] This framework takes the guesswork out of what to do when symptoms change. Here is the decision framework used with patients in clinical care:

Zone Symptoms & Peak Flow Action
GREEN
Doing Well
No cough, wheeze, chest tightness, or shortness of breath during the day or night. Can do usual activities. Peak flow 80% or more of personal best.[9] Continue daily controller medications as prescribed. No additional treatment needed. This is the goal.
YELLOW
Getting Worse
Cough, wheeze, chest tightness, or shortness of breath; or waking at night due to asthma; or can do some, but not all, usual activities. Peak flow 50–79% of personal best.[9] Add your quick-relief medicine as your plan directs (or extra as-needed doses of ICS-formoterol if you use SMART) and keep taking your green zone medicine. If you do not return to the green zone after 1 hour, follow the next step on your plan and contact your physician.[9]
RED
Medical Alert
Very short of breath, or quick-relief medicines have not helped, or cannot do usual activities, or symptoms are the same or worse after 24 hours in the yellow zone. Peak flow less than 50% of personal best. Danger signs: trouble walking and talking due to shortness of breath, or lips or fingernails turning blue.[9] Take the red zone medicine on your plan and call your doctor now. Go to the hospital or call an ambulance if you are still in the red zone after 15 minutes and have not reached your doctor.[9] This is a medical emergency.

What I emphasize to every patient is that the yellow zone is where your decisions matter most. Staying in the yellow zone too long without adjusting treatment or seeking medical advice is how patients end up in the red zone. If you are consistently spending time in the yellow zone, your baseline treatment needs review; that is a signal your asthma is not well controlled, not a reason to keep relying on your rescue inhaler.

Clinical Reasoning: What Your Doctor Is Evaluating

When I evaluate a patient with asthma, I am running through a systematic assessment that goes well beyond "do you wheeze?" Understanding this process helps you communicate more effectively with your physician and understand why we order the tests we do.

Spirometry: The Gold Standard

Spirometry is the primary objective test for diagnosing and monitoring asthma; GINA advises measuring lung function with spirometry, or with a peak flow meter if spirometry is not possible.[1] It measures how much air you can exhale (FVC, forced vital capacity) and how quickly you can exhale it (FEV1, forced expiratory volume in one second). The key diagnostic finding is variable airflow limitation. One GINA criterion in adults is a bronchodilator response in which FEV1 or FVC increases by at least 12% and at least 200 mL from the pre-bronchodilator value.[1]

Peak Flow Monitoring

Peak expiratory flow (PEF) monitoring is a practical home tool that gives you an objective daily measure of your airway function. Your "personal best" peak flow is your best reading when your asthma is well controlled, and your daily readings are compared against it. On the NHLBI action plan, 80% or more of your best is the green zone, 50–79% is yellow, and less than 50% is red.[9] I find peak flow monitoring particularly valuable for patients who are poor perceivers of airway obstruction, because some patients' airways can narrow significantly before they notice symptoms.

What I Am Looking For

  • Symptom pattern: Frequency of daytime symptoms, nighttime awakenings, reliever use, and activity limitation. GINA uses four questions on these domains to judge symptom control, including "Any night waking due to asthma?"[1]
  • Exacerbation history: How many flare-ups in the past 12 months? Any ER visits, hospitalizations, or oral steroid courses? GINA lists a severe exacerbation in the past year, or ever needing intubation or ICU care for asthma, as a risk factor for future exacerbations.[1]
  • Inhaler technique and adherence: GINA advises checking adherence, inhaler technique, risk factors, and comorbidities first, before stepping up treatment.[1]
  • Comorbidities: GINA lists rhinitis, rhinosinusitis, gastroesophageal reflux disease, obesity, obstructive sleep apnea, and depression and anxiety among the conditions to assess, because they can affect asthma symptoms and control.[1]
  • Fractional exhaled nitric oxide (FeNO): In GINA 2025, an elevated FeNO (above 50 ppb in adults and adolescents) can support a diagnosis of Type 2 asthma, but lower FeNO levels do not rule out asthma.[1]

Treatment Options: Step Therapy From Mild to Severe

Asthma treatment follows a stepwise approach. Start at the step that fits the patient, review the response 1–3 months after starting treatment, check adherence, inhaler technique, and comorbidities before stepping up, and consider stepping down once asthma has been well controlled for 3 months or more.[1] The goal is to find the minimum effective treatment. GINA's steps for adults and adolescents are summarized below.[1]

Step Preferred Treatment (GINA Track 1) Alternative Treatment (Track 2)
Step 1–2
(Mild)
As-needed low-dose ICS-formoterol only Step 1: no maintenance ICS; if the reliever is SABA, take ICS whenever SABA is used. Step 2: low-dose maintenance ICS, with SABA or ICS-SABA as reliever
Step 3
(Moderate)
MART (SMART) with low-dose maintenance ICS-formoterol, plus as-needed doses Low-dose maintenance ICS-LABA, with SABA or ICS-SABA as reliever
Step 4
(Moderate-Severe)
MART (SMART) with medium-dose maintenance ICS-formoterol, plus as-needed doses Medium-dose maintenance ICS-LABA, with SABA or ICS-SABA as reliever
Step 5
(Severe)
Add-on LAMA; refer for assessment of phenotype; consider a trial of high-dose maintenance ICS-formoterol; consider an anti-IgE, anti-IL5/5R, anti-IL4Rα, or anti-TSLP biologic Refer for expert assessment, phenotyping, and add-on treatment for severe asthma, including add-on LAMA and biologics

Inhaled Corticosteroids (ICS): The Cornerstone

ICS are the cornerstone of asthma treatment. They reduce airway inflammation, decrease mucus production, and reduce airway hyperresponsiveness. Common ICS include fluticasone, budesonide, beclomethasone, and mometasone. ICS-containing medication markedly reduces the risk of asthma hospitalization and death, a fact that cannot be overstated.[1]

Long-Acting Beta-Agonists (LABA)

LABAs (formoterol, salmeterol, vilanterol) relax airway smooth muscle over many hours. In asthma, a LABA should not be used without an ICS.[1] The ICS-LABA combination is a standard treatment for moderate to severe persistent asthma.

Long-Acting Muscarinic Antagonists (LAMA)

Tiotropium (Spiriva Respimat) was the only LAMA formulation with US FDA approval for asthma treatment when the NAEPP 2020 update was written.[2] It provides additional bronchodilation through a different mechanism than LABAs. In GINA, add-on LAMA is a Step 5 option; compared with ICS-LABA alone, it slightly improves lung function and slightly reduces the risk of exacerbations.[1]

Biologics for Severe Asthma

Biologic therapies have changed the outlook for people with severe asthma that stays uncontrolled despite optimized standard therapy. GINA advises referral for assessment of phenotype, and notes that biologic treatment can be added to maximal treatment, if available and affordable.[1] These are targeted medications that block specific molecules driving airway inflammation:[4]

Biologic Target Key Indication (FDA label) Ages Approved
Omalizumab (Xolair) Anti-IgE Moderate to severe persistent asthma with a positive skin test or in vitro reactivity to a perennial aeroallergen, with symptoms inadequately controlled on inhaled corticosteroids[10] ≥6 years
Mepolizumab (Nucala) Anti-IL-5 Add-on maintenance treatment of severe asthma with an eosinophilic phenotype[11] ≥6 years
Benralizumab (Fasenra) Anti-IL-5Rα Add-on maintenance treatment of severe asthma with an eosinophilic phenotype; reduces blood eosinophils[12] ≥6 years
Dupilumab (Dupixent) Anti-IL-4Rα (blocks IL-4 and IL-13) Add-on maintenance treatment of moderate-to-severe asthma with an eosinophilic phenotype, or oral corticosteroid-dependent asthma; also approved for atopic dermatitis and chronic rhinosinusitis with nasal polyps[13] ≥6 years
Tezepelumab (Tezspire) Anti-TSLP Add-on maintenance treatment of severe asthma; the indication names no phenotype or biomarker[14] ≥12 years
Reslizumab (Cinqair) Anti-IL-5 (IV) Add-on maintenance treatment of severe asthma with an eosinophilic phenotype; given by intravenous infusion only; boxed warning for anaphylaxis[15] ≥18 years

The choice of biologic depends on the patient's asthma phenotype (T2-high or T2-low), blood eosinophil count, IgE level, allergy status, and comorbidities that the same biologic might also address; dupilumab, mepolizumab, and omalizumab are also approved for chronic rhinosinusitis with nasal polyps.[4] Tezepelumab stands out because of its upstream action on the inflammatory cascade through TSLP. It is approved for severe asthma regardless of blood eosinophil, IgE, and FeNO levels, although the review notes it is particularly effective in severe type 2 asthma.[4]

Inhaler Technique: The Most Underestimated Problem in Asthma Care

This may be the most impactful section in this entire guide. Research suggests that up to 90% of people with asthma, depending on the device and patient population, do not use their inhalers correctly.[6] A medication that does not reach the airways cannot treat the airways. Before any physician steps up your asthma therapy, your inhaler technique should be checked; GINA advises checking it at every opportunity.[1]

Common Errors by Device Type

  • Metered-dose inhalers (MDIs): Errors reported in at least half of participants in some studies include failing to breathe out before inhaling, poor coordination of inhaling slowly while firing the inhaler, failing to shake the inhaler, and failing to hold the breath after the dose.[6] Shake the MDI, breathe out fully, press the canister as you start a slow, deep breath, and then hold your breath.
  • Dry powder inhalers (DPIs): Common errors include failing to breathe out away from the inhaler before inhaling and failing to inhale forcefully and deeply.[6] DPIs require a strong, fast inhalation, the opposite of MDI technique, so breathe out away from the device, never into it.
  • Spacers with MDIs: A spacer (valved holding chamber) reduces the coordination problem, because the medication is released into the spacer and the patient inhales from it at their own pace. GINA advises that patients using an ICS in a pressurized metered-dose inhaler use a spacer.[1]

Ask your physician or pharmacist to watch you use your inhaler at every visit. Technique slips over time: approximately 50% of patients fail to maintain correct inhaler technique over time.[6]

Exercise-Induced and Occupational Asthma

Exercise-Induced Bronchoconstriction (EIB)

Exercise-induced bronchoconstriction (EIB), previously called exercise-induced asthma, describes acute airway narrowing that occurs as a result of exercise. A substantial proportion of patients with asthma experience exercise-induced respiratory symptoms, and EIB may also occur in people without known asthma. The transfer of water and heat out of the lower airways during exercise appears to play a role.[7]

EIB should not be a reason to avoid exercise.[1] Management includes:

  • Optimize baseline asthma control: If exercise regularly triggers symptoms, review your daily asthma control with your clinician. For symptoms that continue despite a pre-exercise SABA, the ATS guideline recommends a daily inhaled corticosteroid or a daily leukotriene receptor antagonist.[7]
  • Warm up: For all patients with EIB, the ATS guideline recommends interval or combination warm-up exercise before planned exercise.[7]
  • Pre-exercise treatment: An inhaled SABA is typically taken 15 minutes before exercise, and such use should be less than daily, on average.[7] If ICS-formoterol is your reliever, GINA notes it can also be used before exercise.[1]
  • Environmental considerations: Breathing large volumes of cold, dry air, as in cross-country skiing, has been linked to EIB in athletes.[7]

On testing, the criterion for the percent fall in FEV1 used to diagnose EIB is 10% or more.[7]

Occupational Asthma

GINA advises asking people with asthma whether there are allergens or irritants in the air at work or at home, and whether their asthma is better when they are away from those places.[1] Workplace exposures linked to asthma include isocyanates (paint, foam manufacturing), flour and grain dust (bakeries), wood dust, animal allergens (veterinary work, laboratories), and cleaning products. The diagnosis must be confirmed with objective tests, the patient should be referred to a specialist (if available) without delay, and exposure to the cause must be stopped immediately.[1] Referral to an occupational medicine specialist is appropriate for formal diagnosis and workplace accommodation.

Red Flags: When to Seek Emergency Care

Seek Immediate Emergency Care If You Experience:
  • Quick-relief medicine is not helping: your rescue inhaler gives little or no relief[9]
  • Severe breathlessness: talking in single words, sitting hunched forward, or trouble walking and talking because of shortness of breath[1][9]
  • Blue or gray discoloration of lips, fingernails, or skin (cyanosis): a sign you are not getting enough air[3][9]
  • Peak flow below 50% of personal best: this is the red zone[9]
  • Chest retractions: the chest sucks in between the neck, breastbone, or ribs when breathing in[3]
  • Confusion or drowsiness: in a severe attack, GINA treats these as life-threatening signs that need transfer to intensive care[1]
  • Silent chest: paradoxically, when wheezing quiets during a severe attack, airflow may be so limited that wheezing is no longer possible. GINA lists a silent chest as a life-threatening sign.[1]

Asthma deaths are largely avoidable. You can reduce your risk of death by following your asthma action plan, taking asthma medicines as prescribed, reducing exposure to your triggers, and getting medical help.[3] The single most important thing you can do is have an action plan, know your red zone, and act on it immediately. There is no such thing as being "too cautious" when it comes to a serious asthma flare.

Frequently Asked Questions

Asthma cannot be cured, but it can be effectively controlled. With proper treatment, particularly inhaled corticosteroids, most patients achieve good symptom control and live without significant limitations. Some children with mild asthma may appear to "outgrow" their symptoms, but the underlying airway hyperresponsiveness often persists into adulthood and symptoms can return. The goal of asthma management is sustained control: minimal symptoms, no limitations on activity, normal lung function, and zero exacerbations.

A rescue inhaler (typically albuterol, a short-acting beta-agonist) provides quick relief by relaxing airway muscles within minutes, but does nothing to treat the underlying inflammation. A controller inhaler (typically an inhaled corticosteroid or an ICS-containing combination) reduces chronic airway inflammation and prevents symptoms over time. Under the current GINA 2025 guidelines, the preferred reliever for adolescents and adults is low-dose ICS-formoterol, and with maintenance-and-reliever therapy (SMART) the same inhaler is used both daily and as needed, so many patients no longer need a separate rescue inhaler.[1]

Yes. Exercise is safe and encouraged for people with asthma, and GINA advises that exercise as a trigger should not be avoided.[1] Exercise-induced bronchoconstriction (EIB) occurs in a substantial proportion of people with asthma, but it is manageable: the ATS guideline recommends a warm-up before planned exercise and an inhaled SABA before exercise.[7] If exercise consistently triggers symptoms, your baseline asthma may not be well controlled and your daily treatment may need adjustment.

Nighttime symptoms are a warning sign worth taking seriously. One of the four questions GINA uses to judge symptom control is "Any night waking due to asthma?"[1] Contributors your clinician may look at include allergens in bedding such as dust mites, nasal allergies and postnasal drip, and reflux (GERD), which GINA lists among conditions linked to exacerbation risk.[1] If asthma wakes you at night, your treatment plan likely needs review.

Biologics are injectable medications (reslizumab is given by IV infusion) that target specific molecules in the inflammatory pathways driving severe asthma. GINA positions them as add-on treatment to maximal therapy, after referral for assessment of phenotype.[1] Current biologics include omalizumab (anti-IgE), mepolizumab and reslizumab (anti-IL-5), benralizumab (anti-IL-5 receptor), dupilumab (anti-IL-4/IL-13), and tezepelumab (anti-TSLP). Eligibility depends on your asthma phenotype, blood eosinophil levels, IgE levels, and allergy status. Whether a biologic is working is judged by less systemic corticosteroid use, fewer exacerbations and less healthcare use, and better symptoms and lung function.[4]

Go to the emergency department or call for help if: your quick-relief medicine is not helping; you are very short of breath or have trouble walking and talking; your lips or fingernails turn blue; your peak flow falls below 50% of your personal best (red zone); or you feel the attack is severe and you are frightened.[9] While mild flare-ups can often be managed at home following your asthma action plan, a severe attack that does not respond to rescue medication is a medical emergency. Following your action plan, taking medicines as prescribed, and getting medical help all reduce the risk of dying from asthma.[3]

Triggers and causes are different things, and mixing them up leads to the wrong strategy. Triggers set off symptoms in the moment: GINA lists exposure to allergens you are sensitized to, smoking, vaping, and air pollution as exacerbation risk factors, and viral upper respiratory infections often trigger exacerbations.[1] Cold air, exercise, strong odors, and stress are other common triggers. Causes and risk factors relate to why someone has asthma in the first place: GINA lists allergy features and a family history of asthma or allergy among risk factors for childhood asthma persisting.[1] Avoiding triggers helps day to day, but it does not treat the underlying airway inflammation, which requires anti-inflammatory controller therapy such as inhaled corticosteroids.

Genetics play a real role. Asthma runs in families, and GINA lists a family history of asthma or allergy, along with allergy features, among risk factors for childhood asthma persisting.[1] Genetics alone do not guarantee asthma, though; environmental factors also contribute, and many people with a family history never develop symptoms at all.

The primary objective test is spirometry, which measures how much air you can forcefully exhale (FVC) and how quickly (FEV1). The key diagnostic finding is variable airflow limitation. One GINA criterion in adults is a bronchodilator response in which FEV1 or FVC increases by at least 12% and at least 200 mL from the pre-bronchodilator value.[1] Many patients also use at-home peak flow monitoring to track daily airway function against their personal best. Diagnosis also weighs symptom pattern, including daytime symptoms, nighttime awakenings, rescue inhaler use, and activity limitation, alongside exacerbation history.

Technique matters because a medication that never reaches the airways cannot treat them. Research suggests up to 90% of people with asthma, depending on the device and population, do not use their inhalers correctly.[6] For a metered-dose inhaler, shake it, breathe out fully, then coordinate a slow, deep inhalation with pressing the canister, and hold your breath afterward; firing the inhaler without breathing in slowly and skipping the breath-hold are among the most common mistakes.[6] Dry powder inhalers work differently: they need a strong, deep inhalation, and you should breathe out away from the device first. GINA advises that anyone using an ICS in a pressurized metered-dose inhaler use a spacer.[1] Ask your physician or pharmacist to check your technique at every visit, since it tends to slip over time.

There is no proven home substitute for a rescue inhaler; breathing exercises, steam, or caffeine have not been shown to reliably stop an attack. Sit upright, try to stay calm and breathe slowly, and remove yourself from whatever triggered the episode if possible. If symptoms are mild and improving, monitor closely. But if you are having severe breathlessness, can't speak in full sentences, notice blue or gray lips or fingernails, or symptoms aren't improving within a few minutes, call 911 or get to an emergency department immediately. This is not a situation to wait out without your medication.

Yes. In 2024, 3,279 people in the U.S. died from asthma, and nearly all of these deaths are avoidable with the right treatment and care.[3] Following your asthma action plan, taking asthma medicines as prescribed, reducing exposure to your triggers, and getting medical help all reduce the risk of death.[3] Warning signs that require immediate emergency care include quick-relief medicine that is not helping, trouble walking and talking because of breathlessness, blue lips or fingernails, and a peak flow below 50% of personal best[9], as well as the chest sucking in between the ribs with each breath[3] and confusion or drowsiness.[1] Having an action plan and knowing these red flags are among the most important ways to prevent a fatal outcome.

References

  1. Global Initiative for Asthma (GINA). Summary Guide for Asthma Management and Prevention for Adults, Adolescents and Children 6–11 Years: A Summary Guide for Health Professionals. Updated 2025. Accessed November 7, 2026. https://ginasthma.org/wp-content/uploads/2025/11/GINA-Summary-Guide-2025-WEB_FINAL-WMS.pdf
  2. Cloutier MM, Baptist AP, Blake KV, et al. 2020 Focused Updates to the Asthma Management Guidelines: A Report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group. Journal of Allergy and Clinical Immunology. 2020;146(6):1217-1270. https://pmc.ncbi.nlm.nih.gov/articles/PMC7924476/
  3. Asthma and Allergy Foundation of America (AAFA). Asthma Facts. Last updated April 2026. Accessed November 7, 2026. https://aafa.org/asthma/asthma-facts/
  4. Faria N, Costa MI, Fernandes AL, et al. Biologic Therapies for Severe Asthma: Current Insights and Future Directions. Journal of Clinical Medicine. 2025;14(9):3153. https://pmc.ncbi.nlm.nih.gov/articles/PMC12072268/
  5. American Academy of Allergy, Asthma & Immunology (AAAAI). AIR and SMART Therapy for Asthma. Page dated June 12, 2026. Accessed November 7, 2026. https://www.aaaai.org/tools-for-the-public/conditions-library/asthma/smart
  6. Bosnic-Anticevich SZ, Cvetkovski B, Azzi EA, et al. Identifying Critical Errors: Addressing Inhaler Technique in the Context of Asthma Management. Pulmonary Therapy. 2018;4(1):1-12. https://pmc.ncbi.nlm.nih.gov/articles/PMC6966926/
  7. Parsons JP, Hallstrand TS, Mastronarde JG, et al. An Official American Thoracic Society Clinical Practice Guideline: Exercise-Induced Bronchoconstriction. American Journal of Respiratory and Critical Care Medicine. 2013;187(9):1016-1027. https://doi.org/10.1164/rccm.201303-0437ST
  8. Pollart SM, Elward KS. Overview of Changes to Asthma Guidelines: Diagnosis and Screening. American Family Physician. 2009;79(9):761-767. https://www.aafp.org/pubs/afp/issues/2009/0501/p761.html
  9. National Heart, Lung, and Blood Institute (NHLBI). Asthma Action Plan. NIH Publication No. 20-HL-5251, February 2021. Accessed November 7, 2026. https://www.nhlbi.nih.gov/sites/default/files/publications/Asthma-Action-Plan-2020_rev_508.pdf
  10. U.S. Food and Drug Administration label, via DailyMed. XOLAIR (omalizumab) injection: Prescribing Information. Revised August 2026. Accessed November 7, 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7f6a2191-adfb-48b9-9bfa-0d9920479f0d
  11. U.S. Food and Drug Administration label, via DailyMed. NUCALA (mepolizumab): Prescribing Information. Revised August 2025. Accessed November 7, 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fefb887c-e4ac-431e-8893-e9d1a5a63fea
  12. U.S. Food and Drug Administration label, via DailyMed. FASENRA (benralizumab) injection: Prescribing Information. Revised May 2026. Accessed November 7, 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=da6aca1a-19ed-44a4-abb7-696c7d58b784
  13. U.S. Food and Drug Administration label, via DailyMed. DUPIXENT (dupilumab) injection: Prescribing Information. Revised April 2026. Accessed November 7, 2026. https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=595f437d-2729-40bb-9c62-c8ece1f82780
  14. U.S. Food and Drug Administration label, via DailyMed. TEZSPIRE (tezepelumab-ekko) injection: Prescribing Information. Revised October 2025. Accessed November 7, 2026. https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=60f0aa03-ad25-4d48-80ce-7fcfa76f325f
  15. U.S. Food and Drug Administration label, via DailyMed. CINQAIR (reslizumab) injection: Prescribing Information. Revised June 2020. Accessed November 7, 2026. https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=053b9158-2a5b-48b9-bf47-5fa78a35ec33

About the Author

Parth Bhavsar, MD

Dr. Bhavsar is a board-certified family medicine physician and founder of TeleDirectMD. He manages asthma and prescribes inhaler refills regularly in his virtual practice across 40+ U.S. states + DC. He is fluent in English, Hindi, Gujarati, and Urdu.

Medically reviewed by Parth Bhavsar, MD. Last reviewed February 20, 2026; FAQ section updated August 11, 2026